Advances in highly active antiretroviral therapy (HAART) options for people living with
HIV/AIDS have resulted in decreased morbidity and mortality. To some extent, the role of …

Background People living with HIV have accounted for 38–50% of those affected in the 2022
multicountry mpox outbreak. Most reported cases were in people who had high CD4 cell …

Background To date, only monoclonal antibodies have been shown to be effective for
outpatients with COVID-19. Interferon lambda-1 is a type III interferon involved in innate …

Objectives There is interest in doxycycline as prophylaxis against sexually transmitted
infections (STIs), but concern about antimicrobial resistance (AMR). We conducted a …

Background: The role of remdesivir in the treatment of patients in hospital with COVID-19
remains ill defined in a global context. The World Health Organization Solidarity randomized …

Despite significant efforts, the rate of new HIV infections worldwide remains unacceptably
high, highlighting the need for new HIV prevention strategies. HIV pre-exposure prophylaxis …

Methods The guideline was developed by the Biomedical HIV Prevention Working Group of
the CIHR Canadian HIV Trials Network, with funding from the Canadian Institutes of Health …

Background There is a need for more convenient, less frequent treatment to help address
challenges associated with daily oral HIV treatment in people living with HIV, including …

Background Previous work established non-inferiority of switching participants who were
virologically suppressed from daily oral standard of care to monthly long-acting …

With the emergence of daily oral tenofovir disoproxil fumarate and emtricitabine-based pre-
exposure prophylaxis (PrEP) use in Canada, questions have emerged concerning the …